Alkermes

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Health, Medical Devices, Diabetes, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Research, Control, Overweight, Vivani, Symantec Endpoint Protection, Obesity, Visual perception, Medicine, Amylin Pharmaceuticals, Acceleration, Chemistry, New Drug Application, Patient, Conditional sentence, Weight loss, Stroke, Mouse, Acquisition, Second Sight, Insurance, Trial of the century, Alkermes, Risk, Investment, Injection, Depreciation, Food, Pharmaceutical industry

Research and development expenses: Research and development expenses during the fourth quarter of 2023 were $4.7 million, compared to $4.4 million during the fourth quarter of 2022.

Key Points: 
  • Research and development expenses: Research and development expenses during the fourth quarter of 2023 were $4.7 million, compared to $4.4 million during the fourth quarter of 2022.
  • General and administrative expenses: General and administrative expenses during the fourth quarter of 2023 were $1.5 million, compared to $3.4 million during the fourth quarter of 2022.
  • Other income (expense): Other income (expense), net during the fourth quarter of 2023 was $0.2 million, compared to $0.5 million during the fourth quarter of 2022.
  • Net Loss: The net loss during the fourth quarter of 2023 was $6.0 million, compared to $7.3 million during the fourth quarter of 2022.

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, Inflammation, Bryant University, Alkermes, Chairperson, Audit committee, Business administration, Therapy, Bayer, Patient, LLP, Auditor, Management

Ms. Allen joins the Zenas Board of Directors with over 20 years of experience leading finance, investor relations, business development, human resources, operations and IT at global public and private biotechnology companies.

Key Points: 
  • Ms. Allen joins the Zenas Board of Directors with over 20 years of experience leading finance, investor relations, business development, human resources, operations and IT at global public and private biotechnology companies.
  • “We are pleased to welcome Patty to our Board of Directors,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma.
  • “She has successfully led cross-organizational functions and served on the board of directors of both private and public global biotechnology companies.
  • Prior to Vividion, Ms. Allen was the Chief Financial Officer at Zafgen, Inc. (now Larimer Therapeutics).

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

Retrieved on: 
Thursday, February 8, 2024
ALKS, Webcast, Alkermes

DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.

Key Points: 
  • DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.
  • ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to discuss the company's fourth quarter and year-end 2023 financial results.
  • Management will also discuss financial expectations for 2024 and provide an update on the company.
  • The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com .

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

Retrieved on: 
Thursday, February 8, 2024
ALKS, Webcast, Alkermes

DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.

Key Points: 
  • DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.
  • ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to discuss the company's fourth quarter and year-end 2023 financial results.
  • Management will also discuss financial expectations for 2024 and provide an update on the company.
  • The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com .

Petauri™ Elects William Fleming and James Robinson to Its Board of Directors

Retrieved on: 
Wednesday, December 6, 2023
Paragon, Economics, Policy, Organization, Schering-Plough, Doctor of Pharmacy, DePaul University, Government, Transylvania University, Senior management, Patient, PDP-11, Marketing, University, Cancer, Diversified Pharmaceutical Services, Medicare, Health, General Studies, Biology, Public, Management, Pharmaceutical industry, Pharmacy, Alkermes, Humana

NASHVILLE, Tenn., Dec. 6, 2023 /PRNewswire/ -- Petauri Health, a purpose-built pharmaceutical services platform, announced today that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company's Board of Directors.

Key Points: 
  • NASHVILLE, Tenn., Dec. 6, 2023 /PRNewswire/ -- Petauri Health , a purpose-built pharmaceutical services platform, announced today that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company's Board of Directors.
  • With a nearly 30-year track record at Humana, Dr Fleming is passionate about simplifying healthcare, providing value to consumers, and fostering high-performing teams.
  • Currently the company's Chief Corporate Affairs Officer, William develops and strengthens relationships with government partners to impact public health policy.
  • During his tenure at Humana, William has led various divisions, focusing on clinical integration and improving health outcomes.

Wendy Webber Nelson, PhD and Michael Patsalos-Fox Join SciShield's Board of Directors

Retrieved on: 
Monday, December 4, 2023
ARCH Venture Partners, QPS, Safety, SAN, Cognizant, Vidyo, Mid-America Regional Council, Health, McKinsey & Company, Doctor of Philosophy, Partnership, Management, Alkermes

SAN FRANCISCO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- SciShield, a leading provider of safety and regulatory compliance management software for scientific laboratories, today announced that Wendy Webber Nelson, PhD and Michael Patsalos-Fox have joined its Board of Directors. Both bring decades of experience in corporate leadership and the life sciences industry.

Key Points: 
  • SAN FRANCISCO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- SciShield, a leading provider of safety and regulatory compliance management software for scientific laboratories, today announced that Wendy Webber Nelson, PhD and Michael Patsalos-Fox have joined its Board of Directors.
  • "I am excited to welcome Dr. Wendy Webber Nelson and Michael Patsalos-Fox to the SciShield Board of Directors.
  • Wendy and Michael bring a depth of expertise and customer focus that's truly inspiring, said Nathan Watson, Founder & CEO of SciShield.
  • "We're thrilled to welcome Wendy and Michael to the SciShield Board of Directors," said Neil Willis, member of the SciShield Board of Directors and Partner at Strattam Capital.

Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich

Retrieved on: 
Monday, October 30, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, FDA, Pharmacology, Certified Public Accountant, Therapy, MD, Research and development, Doctor of Philosophy, CNS, State University of New York at Oswego, Development, Alkermes, Growth, Princeton University, Schizophrenia, Executive, State university system, Oswego, Columbia University, Suicidal ideation, Multiple sclerosis, Depression, Patient, Initial public offering, DSM-IV codes, ARCH Venture Partners, Pharmaceutical industry

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat neuropsychiatric disorders, today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.

Key Points: 
  • Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat neuropsychiatric disorders, today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.
  • Dr. Ehrich is currently Executive Vice President and Chief Medical Officer at LifeMine Therapeutics.
  • Prior to LifeMine, Dr. Ehrich was President of Skyhawk Therapeutics and a Venture Partner at 5AM Ventures.
  • Prior, Dr. Ehrich spent 7 years at Merck Research Labs working in clinical pharmacology and clinical development.

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023
DSM-IV codes, MWT, Wireless ambulatory ECG, Congress, Pathology, Dizziness, Idiopathic hypersomnia, Maintenance, Alkermes, Pharmacokinetics, Sleep, Urination, OX2R, Dysfunction, Disease, NT1, Biology, Wakefulness, Sleep onset latency, Safety, Vital signs, ALKS, Patient, Insomnia, Pharmaceutical industry, Narcolepsy

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023
DSM-IV codes, MWT, Wireless ambulatory ECG, Congress, Pathology, Dizziness, Idiopathic hypersomnia, Maintenance, Alkermes, Pharmacokinetics, Sleep, Urination, OX2R, Dysfunction, Disease, NT1, Biology, Wakefulness, Sleep onset latency, Safety, Vital signs, ALKS, Patient, Insomnia, Pharmaceutical industry, Narcolepsy

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.